Biotech Startup Codexis Eyes Emerging Carbon Market

Published on
by
Reuters

Biotech Startup Codexis Eyes Emerging Carbon Market

by
Poornima Gupta

SAN FRANCISCO - U.S. biotechnology company Codexis, which
is partly owned by Royal Dutch Shell Plc, is expanding its product
offerings to target the emerging market for carbon capture and storage,
President and Chief Executive Officer Alan Shaw said on Tuesday.

Coal-fired power plants provide about half of the electricity in
United States, but account for about 80 percent of carbon dioxide
emissions from domestic power generation, making them top targets for
environmentalists.

Coal companies, governments and environmental activists are hoping
for breakthrough technologies that will help trap, transport and bury
underground carbon dioxide, the main greenhouse gas blamed for global
warming.

The Redwood City, California-based company has been mostly focused
on the pharmaceutical and biofuels sector, but is now actively looking
for a partner to help the company market an enzyme that helps captures
carbon dioxide from smokestacks of coal-fired power plants.

"Coal is not going anywhere fast," Shaw said. "There's an urgent need to take carbon dioxide out of coal-fired power stations."

Enzymes are specialized organic substances that act as catalysts in biochemical reactions.

Shaw said the company, which also counts General Electric Co and
Pfizer Inc as shareholders, has successfully completed testing its
product in the last couple of months and is looking to commercialize
the technology.

"We need a partner and are actively talking" to companies, he said,
citing a huge interest in the market for such a technology. "The market
is meeting us more than halfway."

Codexis is seeking a partnership with an industrial equipment maker
that would help engineer a system to introduce the enzyme to the carbon
dioxide on the smokestacks.

A company like GE could be a great partner, Shaw said, but he
declined to say if Codexis was in talks with the industrial
conglomerate.

Shaw said the company plans to aggressively scale-up its plans for the carbon market in 2010.

No commercial scale projects exist to demonstrate the carbon capture
and storage technology, but the European Union has pledged to have
10-12 pilot plants in operation by 2015.

The U.S. Energy Department is also providing up to $408 million in
funding for two projects aimed at developing clean coal technologies.

Shaw said legislation is critical to develop the carbon market.

"They have to put a price on carbon for it to truly work," he said.
The air sector has the most potential if concrete goals for carbon
emissions are put in place at the international talks on climate change
in Copenhagen in December, Shaw added.

POSSIBLE IPO, PROFITABILITY ON TRACK

Codexis "absolutely" is on track to be profitable next year, Shaw
said, adding that revenue is quickly approaching "three digits" in
millions of dollars.

Codexis, which markets enzymes used to speed up or reduce the cost
of manufacturing drugs, chemical and biofuels, had said earlier it
hopes to generate revenue of $50 million to $100 million this year.

Most of Codexis' revenue comes from the pharmaceutical sector.

The company, founded in 2002, came into the spotlight after Pfizer
revealed that Codexis' enzymes were used in the production of its
blockbuster cholesterol-lowering pill Lipitor.

Codexis had withdrawn a $100 million initial public offering last
September because of bad market conditions but could relaunch the
offering as early as 2010, Shaw said.

Shell, which initially held a 13 percent stake in Codexis, recently
increased its stake but did not reveal the size of the new investment.

(Reporting by Poornima Gupta; Editing by Richard Chang)

Share This Article

More in: